Gene Therapy: Novel Conditioning Strategies Replace Busulfan
- This text details research presented on novel approaches to treating Severe Combined Immunodeficiency (SCID), Fanconi Anemia (FA), and Sickle Cell Disease.
- * SCID: Researchers led by Agarwal investigated briquilimab, a humanized monoclonal antibody, as a non-toxic option to donor engraftment for SCID patients who had failed previous transplants.
- * problem: Myeloablative conditioning with busulfan for sickle cell disease can cause infertility and organ damage, deterring patients from treatment.
Summary of Research Presented: Briquilimab & Novel Gene Therapy Approaches for Immunodeficiencies & Sickle Cell Disease
This text details research presented on novel approaches to treating Severe Combined Immunodeficiency (SCID), Fanconi Anemia (FA), and Sickle Cell Disease. here’s a breakdown:
1. Briquilimab for SCID & Fanconi Anemia:
* SCID: Researchers led by Agarwal investigated briquilimab, a humanized monoclonal antibody, as a non-toxic option to donor engraftment for SCID patients who had failed previous transplants.
* Key Findings: The study (NCT02963064) showed briquilimab was safe, led to robust myeloid engraftment, and didn’t cause adverse events or myelosuppression.A dose of 0.6 mg/kg was found optimal for consistent engraftment and immune cell production. Patients could receive treatment as outpatients.
* Fanconi Anemia (FA): Agarwal’s team explored briquilimab in combination with other drugs (anti-thymocyte globulin, cyclophosphamide, fludarabine, and rituximab) for FA patients with bone marrow failure, aiming to avoid the toxic effects of busulfan.
* Key Findings: The phase 1b trial (NCT04784052) demonstrated safety, with no treatment-emergent adverse events or graft-versus-host disease. Patients showed rapid neutrophil engraftment (median 11 days) and stable donor chimerism up to 2 years post-treatment.
2. Novel Gene Therapy for Sickle Cell Disease (“ESCAPE” Strategy):
* problem: Myeloablative conditioning with busulfan for sickle cell disease can cause infertility and organ damage, deterring patients from treatment.
* demirci’s Approach: Developed a non-genotoxic, fertility-preserving gene therapy using base editing (preferred over CRISPR-Cas9 due to avoiding DNA breaks).
* “ESCAPE” Mechanism: Hematopoietic stem cells are edited to modify the CD117 binding site and increase fetal hemoglobin expression.The modified cells can then ”escape” destruction by an anti-CD117 antibody used for conditioning, while unedited host cells are eliminated. This minimizes damage to healthy tissues.
In essence, the research highlights promising new strategies to improve treatment outcomes and reduce toxicity for patients with these serious genetic disorders. Briquilimab offers a potential alternative to conventional transplantation approaches, while Demirci’s gene therapy aims to overcome the limitations of current conditioning regimens for sickle cell disease.